araag2/HINT huggingface dataset:
Clinical trial NCT00003256 (phase 2, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: alvocidib
SMILES: CN1CC[C@@H]([C@H](O)C1)C1=C(O)C=C(O)C2=C1OC(=CC2=O)C1=CC=CC=C1Cl
Eligibility criteria:

        PATIENT CHARACTERISTICS:

          -  Performance Status: ECOG 0-2

          -  Life Expectancy: At least 3 months

          -  WBC at least 3,000/mm3

          -  Absolute neutrophil count at least 1,200/mm3

          -  Platelet count at least 100,000/mm3

          -  Hemoglobin at least 8 g/dL

          -  Bilirubin no greater than 1.5 mg/dL

          -  SGOT no greater than 2.5 times normal

          -  Creatinine no greater than 1.5 mg/dL

          -  Prostate-specific antigen at least 10 ng/mL (if bone only disease)

          -  No prior or concurrent maligancies within 5 years, except nonmelanoma skin cancer

          -  No serious medical illness

          -  No cord compression symptoms

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy

          -  No prior suramin therapy

          -  Prior or concurrent use of luteinizing hormone-releasing hormone allowed (no other
             concurrent hormonal therapy)

          -  No prior anti-androgen therapy within 4 weeks of study

          -  At least 4 weeks since prior radiotherapy

          -  No prior strontium therapy
Clinical trial NCT00710684 (phase 2, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: sb-742457 15mg, sb-742457 35mg, placebo, donepezil 5-10mg
SMILES: O=S(=O)(C1=CC=CC=C1)C1=CN=C2C(C=CC=C2N2CCNCC2)=C1, O=S(=O)(C1=CC=CC=C1)C1=CN=C2C(C=CC=C2N2CCNCC2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, O=S(=O)(C1=CC=CC=C1)C1=CN=C2C(C=CC=C2N2CCNCC2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects and their caregivers must provide informed consent prior to study entry.

          -  Subjects must have a clinical diagnosis of probable mild-to-moderate Alzheimer's
             disease with no evidence of disorders that are thought to be the cause of, or
             contributing to the severity of the subject's dementia and a documented history of at
             least 6 months of ongoing donepezil therapy with stable dosing for at least the last 2
             months.

          -  Subjects must have a regular caregiver who is willing to attend visits, oversee the
             subject's compliance with the study and report on the subject's status.

          -  Female subjects of child-bearing potential must agree to abstinence or an approved
             form of birth control.

          -  Subjects must have adequate blood pressure and laboratory values.

        Exclusion Criteria:

          -  Subjects with a diagnosis of possible, probable or definite vascular dementia may not
             participate.

          -  Subjects with known hypersensitivity to sunlight or a history of seizures, previous
             exposure to SB-742457, taking agents for which there is a theoretical risk of
             interaction with SB-742457, or taking medication for Alzheimer's disease or centrally
             acting agents which might impact study outcomes may not participate.
Clinical trial NCT00404703 (phase 2, status: terminated)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: bevacizumab [avastin], platinum-based chemotherapy
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Reason stopped: 
    primary (safety) endpoint reached
  
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, >=18 years of age;

          -  documented squamous non-small cell lung cancer;

          -  stage IIIb with pleural or pericardial effusion, stage IV, or recurrent disease;

          -  suitable for platinum-based treatment as first line chemotherapy.

        Exclusion Criteria:

          -  prior systemic anti-tumor therapy;

          -  prior radiotherapy for treatment of patient's current stage of disease;

          -  other primary tumors within last 5 years, except for controlled limited basal cell or
             squamous cancer of the skin, or cancer in situ of the cervix;

          -  major surgery, open biopsy or significant traumatic injury within 28 days prior to
             randomization.
Clinical trial NCT00557817 (phase 2/phase 3, status: completed)
Conditions: hematological malignancies
ICD codes: P61.9, P61.8, O28.0, T45.8X6S, T45.96XS, T45.8X3S, T45.8X4S
Drugs: darbepoetin alpha (aranesp), iron saccharate (venofer)
SMILES: O.O.O.[OH-].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O
Eligibility criteria:

        Inclusion criteria:

          -  Male or female; female patients must use a reliable contraception method

          -  Age > 16 yrs and < 70 yrs

          -  No terminal organ failure

          -  Written informed consent given by patient or his/her guardian if of minor age.

          -  Adequate iron stores (serum ferritin > 100 µg/L) on day 21 post-transplant.

          -  Adequate marrow recovery, as shown by: neutrophils > 1,000/µL, platelet transfusion
             independence

          -  PBSC (not marrow) transplantation

        Exclusion criteria:

          -  HIV positive

          -  Known allergy to recombinant human erythropoietin or i.v. iron saccharate

          -  Evidence of active hemorrhage, hemolysis, vitamin B12 or folate deficiency on day 28
             post-transplant (inclusion into the protocol may then be delayed up until day 42 if
             the problem is resolved)

          -  Uncontrolled infection, arrythmia or hypertension on day 28 post-transplant (inclusion
             into the protocol may then be delayed up until day 42 if the problem is resolved)

          -  Evidence of severe iron overload (transferrin saturation > 60%, serum ferritin > 2500
             µg/L on day 21 post-transplant)
Clinical trial NCT01436890 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: revamilast, revamilast, revamilast, placebo
SMILES: [O-][N+]1=CC(Cl)=C(NC(=O)C2=CC=C(OC(F)F)C3=C2C2=C(O3)C=CN=C2)C(Cl)=C1, [O-][N+]1=CC(Cl)=C(NC(=O)C2=CC=C(OC(F)F)C3=C2C2=C(O3)C=CN=C2)C(Cl)=C1, [O-][N+]1=CC(Cl)=C(NC(=O)C2=CC=C(OC(F)F)C3=C2C2=C(O3)C=CN=C2)C(Cl)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. The patient provides written informed consent to participate in the study

          2. Male or female patient aged 18 to 65 years

          3. Documented diagnosis of asthma

          4. Forced Expiratory Volume in One Second (FEV1) between 50% and 80% of the predicted
             value

          5. Patient judged by the investigator to be in otherwise good stable health based on
             medical history, physical examination, and routine laboratory data

          6. Female participants must have a negative pregnancy test at screening visit

          7. Males must agree to use barrier contraception while on study medication and for 90
             days after taking the last dose of study medication

        Exclusion Criteria:

          1. Pregnant or lactating women

          2. Female subjects on hormone replacement therapy or hormonal contraceptives

          3. Suffering from relevant lung diseases (other than asthma) causing impairment in lung
             function

          4. Past smoker with a history of ≥10 pack per year or current smoker

          5. Recent change in the patient's usual asthma treatment

          6. Patients with risk factors for asthma exacerbation during the study, including (any of
             the following):

               -  Current requirement for > 8 puffs per day of reliever medication.

               -  Hospitalization for asthma

               -  Treatment with systemic corticosteroid therapy within 3 months

          7. Evidence of current or recent neoplastic disease

          8. Clinically significant cardiovascular, haematological, endocrine, neurological,
             gastrointestinal, psychiatric, metabolic, immunologic, infectious, hepatic, renal,
             gynaecological disease or other condition that the investigator considers detrimental
             to the patient's participation in the study or that may prevent the successful
             completion of the study

          9. Positive serology for an infectious disease (including hepatitis B or C) at screening
             and known case of human immunodeficiency virus [HIV]

         10. Patients who have been hospitalized for any psychiatric illness in the past year, or
             are diagnosed with major depression

         11. Clinically significant ECG Abnormality at baseline

         12. Patients with documented or suspected or current history of alcohol and drug abuse

         13. Patients who have undergone lung surgery in the previous year

         14. Participation in an investigational drug trial during 30 days preceding screening
Clinical trial NCT00235937 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: anastrozole and goserelin
SMILES: CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent, premenopausal women 18 years or older, histologically or
             cytologically confirmed locally advanced or metastatic breast cancer, suitable for
             endocrine treatment, no curative treatment available,, one or more measurable lesions,
             life expectancy more than 6 months, normal biological parameters.

        Exclusion Criteria:

          -  Presence of life-threatening metastases, previous endocrine therapy or chemotherapy
             for advanced or metastatic disease, any previous treatment with hormone (LH-RH) severe
             or uncontrolled systemic disease, pituitary adenoma, High risk of medullar
             compression.
Clinical trial NCT01251406 (phase 2, status: completed)
Conditions: chronic heart failure
ICD codes: I50.812, I50.22, I50.32, I50.813, I50.23, I50.33, I50.42
Drugs: placebo, rhnrg-1 dose 1, rhnrg-1 dose 2
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age > 18 years.

          -  Male or female subjects.

          -  Have chronic heart failure defined as NYHA classification of II or III.

          -  Be on a stable regimen of ACEI/ARB and/or beta-blocker 3 months prior to receiving
             study medication and are expected to remain on a stable HF medication regime
             throughout the duration of the trial.

          -  Left ventricular ejection fraction (LVEF) of < 35% as determined at screening by 2-D
             echocardiography.

          -  Is able to understand and provide informed consent.

          -  If subject has dilated cardiomyopathy, ischemic heart disease or corrected valvular
             heart disease, and had surgery to repair or replace value, the surgery must have been
             performed 3 months prior to receiving study medication and the surgical area is
             functioning normally.

          -  Proper birth control must be used at least 3 weeks prior to the study (women only),
             during the infusion period of study drug (men and women), 4-weeks after study drug
             administration (men and women) and the remaining 11 months in the study follow-up
             (women). Women must have a negative pregnancy test at screening.

          -  No greater than mild pericardial effusion < 0.5 cm on echocardiography (roughly
             corresponds to < 100 mL).

          -  Have an implantable cardioverter-defibrillator (ICD). The ICD should have been
             implanted at least 3 months prior to receiving study medication. Patients should
             undergo interrogation of their ICDs between 1 and 7 days before randomization to drug
             for the previous thirty (30) days. This interrogation would include surveillance for
             ventricular arrhythmias as well as assessment of ICD discharge(s) and/or
             anti-tachycardia pacing.

        Exclusion Criteria:

          -  Has chronic heart failure classified as NYHA Class I or IV.

          -  Has a history of any malignancy or positive test as specified in the pre-cancer
             screening.

          -  Have other conditions which in the opinion of the investigator preclude participation
             in the study, e.g. serious co-morbidity, known or suspected substance abuse or
             non-compliance.

          -  Has a body weight >350lbs.

          -  Has had any cause hospitalization 30 days prior to screening.
Clinical trial NCT00665847 (phase 2, status: completed)
Conditions: hiv-1
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: etravirine (tmc125), optimized background regimen (obr)
SMILES: CC1=CC(=CC(C)=C1OC1=C(Br)C(N)=NC(NC2=CC=C(C=C2)C#N)=N1)C#N, CC(C)C1=NN=C(C)N1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  HIV-1 infected

          -  Body weight according to age within the 10-90th percentile of CDC growth chart

          -  On steady antiretroviral therapy regimen for at least 8 weeks at screening and willing
             to remain on that regimen until baseline

          -  HIV viral load of 1,000 copies/ml or greater at study entry

          -  Parent or legal guardian willing to provide informed consent, if necessary

        Exclusion Criteria:

          -  The Key Exclusion Criteria are: Evidence of resistance to etravirinel Any grade 3 or 4
             toxicity (More information available in the protocol)

          -  Use of disallowed concomitant therapy (specified in the protocol)

          -  Currently active AIDS defining illness (category C)

          -  Active hepatitis A, B or C virus infection

          -  Any clinically significant diseases or findings that, in the opinion of the
             investigator, would interfere with the study

          -  Receipt of any ARV or non-ARV investigational medication or investigational vaccine
             within 30 days prior to screening

          -  History of clinically significant allergy or hypersensitivity to any of the excipients
             of the investigational medication (TMC125)
Clinical trial NCT00481520 (phase 2, status: completed)
Conditions: alzheimer disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: sam-531
SMILES: CN(C)CCCOC1=CC=C2NN=C(C2=C1)S(=O)(=O)C1=C2C=CC=CC2=CC=C1
Eligibility criteria:

        Inclusion Criteria

          1. Signed and dated written informed consent obtained from the subject or the subject's
             legally authorized representative (LAR) or next of kin (if applicable), in accordance
             with the local regulations. The subject's caregiver must also consent to participate
             in the study.

          2. Diagnosis of probable Alzheimer's Disease according to National Institute of
             Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related
             Disorders Association (NINCDS-ADRDA) criteria.

          3. Men and postmenopausal or surgically sterile women aged from 50 to 90 inclusive.
             Postmenopausal women must have had 12 months of spontaneous amenorrhea. Surgically
             sterile women are defined as having a hysterectomy, bilateral ovariectomy
             [oophorectomy], or bilateral tubal ligation. Men who are sexually active will need to
             agree to use a form of contraception that is satisfactory as per the investigator.

          4. Able to participate in all scheduled evaluations with a high probability of completing
             all required procedures and neuropsychological tests.

        Exclusion Criteria

          1. Significant neurological disease other than Alzheimer's disease, which may affect
             cognition (eg, epilepsy, Parkinson disease).

          2. Current diagnosis of a major depressive disorder or other major psychiatric symptom
             according to the criteria of Diagnostic and Statistical Manual of Mental Disorders,
             Fourth Edition Text Version (DSM-IV-TR).

          3. Current clinically significant systemic illness, which is likely to deteriorate or
             affect the subject's safety, influence cognitive assessment or ability to complete the
             study.

          4. Any clinically important deviation from normal limits in physical and neurological
             examination, vital signs, on electrocardiogram (ECG) or clinical laboratory test
             results that could compromise the study or be detrimental to the subject.
Clinical trial NCT00427427 (phase 2, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: trastuzumab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    lack of accrual
  
Eligibility criteria:

        Inclusion Criteria:

          1. Confirmed non-metastatic infiltrating carcinoma of the breast.

          2. HER-2 amplified (FISH +) determination in 2004 or thereafter.

          3. ECOG performance status 0-2.

          4. Patients 18 years of age or older.

          5. HER-2 status is determined by FISH test.

          6. The following criteria are applicable to the trastuzumab treatment group:

               -  Normal LVEF as determined by ECHO or MUGA. If baseline LVEF > 75%, then LVEF
                  shall be repeated to determine if falsely elevated.

               -  Adequate bone marrow function as indicated by the following: ANC >1500/mL,
                  Platelets >/=100,000/mL, Hemoglobin >9 g/dL

               -  Adequate renal function,as indicated by serum creatinine </= 1.5 x ULN

               -  Adequate liver function, as indicated by total bilirubin </= 1.5 x ULN

               -  AST and ALT < 2 x ULN unless related to primary disease.

               -  If female of childbearing potential, pregnancy test (blood or urine) is negative
                  and she agrees to use effective birth control method for the duration of the
                  study.

          7. Signed informed consent has been obtained.

        Exclusion Criteria:

          1. Non-confirmed HER-2 positive by FISH infiltrating carcinoma of the breast.

          2. Evidence of metastatic disease.

          3. Previous trastuzumab treatment.

          4. Concurrent anticancer treatment other than hormonal agents (tamoxifen, aromatase
             inhibitors) or radiotherapy.

          5. Patient with history of or active cardiac disease, including cardiomyopathy,
             congestive heart failure, prior myocardial infarction, or arrhythmia.

          6. Symptomatic intrinsic lung disease resulting in dyspnea at rest.

          7. Concurrent life-limiting disease with a life expectancy of less than one year.

          8. Pregnancy, nursing women, and fertile women who do not practice birth control.

          9. Inability to give informed consent.
Clinical trial NCT00063258 (phase 2, status: terminated)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: tarceva (osi-774), paclitaxel, carboplatin
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, N[C@@H](CCCNC(N)=N)C(O)=O
Reason stopped: 
    low accrual rate
  
Eligibility criteria:

        Inclusion Criteria:

          1. Must have signed consent for LAB03-0383

          2. Pathologic documentation of NSCLC

          3. Stage IIIA and IIIB (T4 satellite nodules or invasion into T4 structures but no
             malignant effusion) with all patients requiring mediastinoscopy positive N2,
             potentially resectable disease. N3 disease is excluded.

          4. Measurable disease

          5. Zubrod performance status of 0 or 1

          6. Calculated post-resectional FEV1 of > 40%

          7. WBC>4000/l, ANC>1500/l, platelets > 100,000/l

          8. Serum creatinine < 1.5 ULN or calculated creatinine > 50 cc/min

          9. Total serum bilirubin <1.5 x ULN or SGPT or SGOT < 2 X ULN

         10. The following must be completed within 28 days of registration: CT scan of the chest
             and upper abdomen to include the adrenals. Mediastinoscopy to document ipsilateral
             nodal involvement and exclude N3 disease Blood tests, and pulmonary function tests The
             following must be completed within 2 months of registration: Pet scan If a CT PET is
             done more than 28 days, only the CT needs to be repeated and a bone scan to rule out
             bone metastases

        Exclusion Criteria:

          1. No prior chemotherapy or radiation for NSCLC

          2. No prior malignancy is allowed except for adequately treated basal cell or squamous
             cell skin cancer, in situ cervical cancer, or other cancer from which the patient has
             been disease-free for at least five years. If patient is suspected or known to have
             basal or squamous skin cancer, this maybe treated after induction chemotherapy is
             completed at the time of thoracotomy.

          3. No post-obstructive pneumonia or other serious infection or other serious underlying
             medical condition that would impair ability of patient to receive protocol treatment,
             including prior allergic reactions to drugs containing cremophor.

          4. Pregnant or nursing women may not participate